CURIS INC (CRIS) Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small-molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single-arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes. The company’s pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral, small-molecule antagonist designated as CA-170 that selectively targets PD-L1 and VISTA; and CA-327, an oral, small molecule, TIM3/PD-L1, which is a molecule antagonist of PD-L1 and TIM3. It has collaboration agreements with Genentech Inc., or Genentech and F. Hoffmann-La Roche Ltd, or Roche, for the commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway antagonist for the treatment of advanced basal cell carcinoma, or BCC; Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and also licensed three programs under the Aurigene collaboration, including emavusertib. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.
Sector: Biological Products, (No Diagnostic Substances)
Industry: Biotechnology
Curis, Inc. NASDAQ:CRIS Healthcare · Biotechnology
Mkt Cap $4.01M
Vol 0
$ Vol 0
RVOL 0
Earnings 0
Press Release ⚠ 4
Curis, Inc. Announces Pricing of $8.5 Million Private Placement Priced At-the-Market Under Nasdaq Rules with Existing Healthcare Focused Institutional Investors
Curis priced a $8.5M private placement of 16,666,680 shares (or pre-funded warrants) with accompanying warrants at an effective $0.51 per share, in an at-the-market offering under Nasdaq rules.
The deal includes deep dilution mechanics: existing warrants previously exercisable at $15.00 and $1.75 are repriced down to $0.60, and new penny-warranted shares carry five-and-a-half-year terms.
Proceeds fund operations only through initial CLL data in 5-10 patients in December 2026, and the company explicitly states it lacks sufficient cash for the next 12 months, signaling further capital raises are likely.
• 16d ago AI analysis › Press Release
Curis, Inc. Announces Pricing of $5.6 Million Public Offering
Curis priced a $5.6 million public offering involving 3.73 million shares of common stock and warrants at a combined price of $1.50 per share.
The company intends to use the net proceeds to fund research and development activities, as well as for working capital and general corporate purposes.
A.G.P./Alliance Global Partners is acting as the lead placement agent, with Laidlaw & Company (UK) Ltd. as co-placement agent, and the offering is expected to close on August 14, 2026.
• 2mo ago AI analysis › Press Release ⚠ 2
Curis Doses First Five Patients in TakeAim CLL Study
Curis announced the dosing of the first five patients in the Phase 2 TakeAim CLL study, which evaluates emavusertib in combination with zanubrutinib for Chronic Lymphocytic Leukemia.
The company reaffirmed its guidance to report initial data on 5-10 patients in December 2026, noting that enrollment across 11 open sites is exceeding expectations.
Management reported that the combination appears well tolerated and shows early evidence of deepening responses, potentially addressing unmet needs in the current standard of care.
• 3mo ago AI analysis › Press Release ● Major ⚠ 2
Curis Announces Positive Emavusertib Update
Curis reported positive updated clinical data from its registrational TakeAim Lymphoma study in PCNSL, showing a 100% overall response rate (ORR) in evaluable BTKi-naïve patients and a 33% ORR in evaluable BTKi-experienced patients.
In the TakeAim CLL study, the company increased its guidance for year-end data to 5-10 patients, up from a previous estimate of 5, with 10 patients currently consented.
Management noted that the ongoing PCNSL study could support an application for accelerated approval based on prior feedback from the FDA and EMA.
• 3mo ago AI analysis › Press Release ⚠ 2
Curis Consents First Six Patients in TakeAim CLL Study
Curis has consented the first six patients in its TakeAim CLL Phase 2 study evaluating emavusertib in combination with zanubrutinib.
The company reaffirmed its guidance to dose five patients by the end of July 2026, with initial data expected in December 2026.
The study targets patients with partial response and measurable residual disease, aiming to achieve dual blockade of NF-kB via the TLR and BCR pathways.
• 3mo ago AI analysis › Press Release ● Major ⚠ 2
Curis Announces Eleven Active Clinical Sites in TakeAim CLL Study, Reaffirms Patient Dosing Guidance, and Reports Stockholder Approval of Reverse Stock Split
Curis announced that eleven clinical sites are now open for enrollment in its Phase 2 TakeAim CLL study evaluating emavusertib in combination with zanubrutinib.
The company reaffirmed guidance for the dosing of the initial five patients by the end of July 2026, with data expected in December 2026.
Stockholders approved a reverse stock split proposal at a ratio ranging from 1-for-5 to 1-for-25 to regain compliance with Nasdaq's $1.00 minimum bid price rule.
• 4mo ago AI analysis › Press Release ● Major
Curis Provides First Quarter 2026 Business Update
prnewswire.com • 5mo ago Press Release
Curis to Report First Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on May 12, 2026
Curis announced it will report its first quarter 2026 financial and operating results on May 12, 2026, after the market close.
Management will host a conference call and webcast at 4:30 p.m. ET on the same day to discuss the results.
The company's focus remains on emavusertib (CA-4948), an IRAK4 and FLT3 inhibitor, currently in Phase 1/2 and Phase 2 studies for lymphoma and CLL.
• 5mo ago AI analysis › 
